|
|
Article: Amgen Offers More On Aranesp, Starts Phase III Loading' Trial.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Girding for a marketplace battle in oncology, Amgen Inc. offered encouraging data regarding its anemia product Aranesp (darbepoetin alfa), approved in September for dialysis and nondialysis patients with chronic renal failure and already being used off-label for cancer patients.
"We've started to enroll in an enormous global Phase III study," said Amgen spokesman Michael Beckerich, adding that the company has not disclosed a completion date.
"We haven't given any specifics on location, patients or endpoints," he told BioWorld Today. "It's going to have to be a very large study."
Extended-release Aranesp allows for ...